You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 8,921,374


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,921,374
Title:Itraconazole compositions and dosage forms, and methods of using the same
Abstract: The disclosure relates to, among other things, pharmaceutical compositions, such as solid oral dosage forms, comprising itraconazole, methods of making the compositions, and methods of using the same for treating disorders including, but not limited to, fungal infections.
Inventor(s): Mudge; Stuart James (Northcote, AU), Hayes; David (Rostrevor, AU), Lukas; Stefan (Manningham, AU)
Assignee: Mayne Pharma International Pty Ltd (Melbourne, AU)
Application Number:13/924,222
Patent Claims: 1. An oral pharmaceutical composition comprising about 65 mg of itraconazole and one or more pharmaceutically acceptable polymers in a matrix system, wherein the composition exhibits an AUC.sub.0-t which is 80% to 125% of about 650 h*ng/ml to about 1200 h*ng/ml following administration of the composition to a subject under fed conditions, and the composition under fed conditions is therapeutically similar to a composition containing about 100 mg of itraconazole, sugar spheres, hydroxypropyl methyl cellulose, and polyethylene glycol in a capsule shell, under fed conditions.

2. The oral pharmaceutical composition of claim 1, wherein the composition exhibits a C.sub.max which is 80% to 125% of about 65 ng/ml to about 100 ng/ml following administration of the composition to a subject under fed conditions.

3. The oral pharmaceutical composition of claim 1, which under fasting conditions is therapeutically similar to a composition containing about 100 mg of itraconazole sugar spheres, hydroxypropyl methyl cellulose, and polyethlene glycol in a capsule shell, under fed conditions.

4. An oral pharmaceutical composition comprising about 65 mg of itraconazole and one or more pharmaceutically acceptable polymers in a matrix system, wherein the composition exhibits an AUC.sub.0-t which is 80% to 125% of about 450 h*ng/ml to about 900 h*ng/ml following administration of the composition to a subject under fasting conditions, and the composition under fed conditions is therapeutically similar to a composition containing about 100 mg of itraconazole, sugar spheres, hydroxypropyl methyl cellulose, and polyethylene glycol in a capsule shell, under fed conditions.

5. The oral pharmaceutical composition of claim 4, which under fasting conditions is therapeutically similar to a composition containing about 100 mg of itraconazole, sugar spheres, hydroxypropyl methyl cellulose, and polyethylene glycol in a capsule shell, under fed conditions.

6. The oral pharmaceutical composition of claim 4, which exhibits an AUC.sub.0-t which is 80% to 125% of about 650 h*ng/ml to about 1200 h*ng/ml following administration of the composition to a subject under fed conditions.

7. The oral pharmaceutical composition of claim 1, which exhibits a ratio in the range from about 0.70 to about 1.43 for AUC0-t between the oral pharmaceutical composition and a composition containing about 100 mg of itraconazole, sugar spheres, hydroxypropyl methyl cellulose, and polyethylene glycol in a capsule shell, with the 90% confidence interval.

8. The oral pharmaceutical composition of claim 4, which exhibits a ratio in the range from about 0.70 to about 1.43 for AUC0-t between the oral pharmaceutical composition and a composition containing about 100 mg of itraconazole, sugar spheres, hydroxypropyl methyl cellulose, and polyethylene glycol in a capsule shell, with the 90% confidence interval.

9. The oral pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable polymer is an enteric polymer or an acid-resistant polymer.

10. The oral pharmaceutical composition of claim 4, wherein the pharmaceutically acceptable polymer is an enteric polymer or an acid-resistant polymer.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.